np event 2254995 0E193A 1
Feb 10, 2022
- Feb 9, 2023

Advances in Disease Management of Generalized Myasthenia Gravis by Reducing Levels of IgG Autoantibodies

EARNed Credits

1.0

AMA PRA Category 1 CreditTM

Screen Shot 2022 02 07 at 9.44.26 AM

Overview

This CME/CE program will highlight recent advances in disease management of generalized myasthenia gravis (MG) by reducing levels of IgG autoantibodies. The expert faculty, led by Dr. James F. Howard, will first cover the pathophysiology of MG, including therapeutic approaches and general limitations for current immunosuppressant therapies. Following, current clinical trial data of FcRn Inhibitors in myasthenia gravis will be analyzed, along with therapies in the pipeline. The faculty will conclude with a discussion of practical considerations for implementing tailored treatment plans in practice. Upon conclusion of this program, clinicians will be better equipped to treat and manage their patients with MG.

Who Should Attend

MG and other neuromuscular disease specialists, neuroimmunologists, general neurologists, other clinicians who manage patients with MG

Provided By

Course Faculty

bril
Vera Bril, MD
Professor of Neurology Ellen & Martin Prosserman Centre for Neuromuscular Diseases University Health Network University of Toronto Toronto, Ontario, Canada
Howard Headshot  e1721236596371
James F. Howard Jr., MD
Professor of Neurology, Medicine & Allied Health
Departments of Neurology, Medicine & Allied Health
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Vissing
John Vissing, MD, DMSci
Professor of Neurology Director, Neuromuscular Clinic and Research Unit University of Copenhagen Copenhagen Neuromuscular Center Copenhagen, Denmark

Learning Objectives

1

Understand the pathophysiology of generalized myasthenia gravis and the rationale for targeted, non-steroidal immune-mediated therapy

2

Explain the mechanism of action of FcRn inhibitors in MG and review recent clinical trial data

3

Plan implementation of therapy with emerging and approved FcRn inhibitors into current treatment guidance for individualized management of generalized MG by the interprofessional team

Course Agenda

1

Pathophysiology of Generalized Myasthenia Gravis and the Rationale for Targeted, Non-Steroidal Immune-Mediated Therapy

2

FcRn inhibitors in MG: Mechanism of Action, Clinical Trial Data

3

Implementation of Therapy with Emerging and Approved Novel Agents for Individualized Management of Generalized MG by the Interprofessional Team

Additional Course Information

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
James F. Howard Jr., MD (Course Chair) Consultant/Advisor: Alexion Pharmaceuticals, Inc.; argenX; Horizon Therapeutics plc; Immunovant, Inc.; Ra Pharmaceuticals; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis U.S. LLC; Toleranzia AB; UCB S.A.; Viela Bio, Inc. 

Research/Grant Support: Alexion Pharmaceuticals, Inc.; argenX; Cartesian Therapeutics; The Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; Ra Pharmaceuticals; UCB S.A.

Stock: Johnson & Johnson Services, Inc.; Pfizer Inc.; GlaxoSmithKline; General Electric

Vera Bril, MD Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc; argenX; Akcea Therapeutics; CSL; Immunovant, Inc.; Ionis Pharmaceuticals; Janssen Global Services, LLC; Momenta Pharmaceuticals, Inc.; Roche; Takeda Pharmaceutical Company Limited 

Research/Grant Support: Alexion Pharmaceuticals, Inc.; Immunovant, Inc.; Ionis Pharmaceuticals; Takeda Pharmaceutical Company Limited; UCB S.A.

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.

Participants should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been supported by an educational grant from argenX.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and argenX do not recommend the use of any agent outside of the labeled indications.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 80% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

For all CE inquiries or special needs, please contact admin@academiccme.com.

np event 2254995 0E193A 1
Feb 10, 2022
- Feb 9, 2023

Advances in Disease Management of Generalized Myasthenia Gravis by Reducing Levels of IgG Autoantibodies

Related Webcast Courses

np document 888746 0E193A 5
Neurology
A Scientific and Practical Guide to the Administration and Monitoring of FcRn Blockers for...
np document 888746 0E193A 5
Neurology
Differentiating S1P-Based Therapeutics for the Treatment of Patients with Multiple Scleros...
np document 888746 0E193A 5
Neurology
Review of New and Emerging Therapies that Improve Tolerability and Adherence in Patients w...